N. Mucciardi et al., SUCCESSFUL CLINICAL OUTCOMES AND COST SAVINGS ASSOCIATED WITH A 12-HOUR IV CEFTIZOXIME REGIMEN, Formulary, 31(4), 1996, pp. 304-306
A medication use monitor (MUM) was conducted at our institution to doc
ument utilization and outcome data for IV ceftizoxime (Cefizox) dosed
at 12-hour intervals. This evaluation followed the implemenentation of
a therapeutic interchange policy of IV ceftizoxime for-IV ceftriaxone
(Rocephin). A satisfactory clinical outcome was achieved in 99% (457
of 460) of the cases. Estimated cost-avoidance exceeded $80,000 for 1
year.